EXCLUSIVE: TransCode’s RNA Therapeutic Achieves 64% Stable Disease Rate In Colorectal Cancer Phase 1 Study

All NewsJune 3, 2026

TransCode Therapeutics announced successful completion of Phase 1a clinical trial for TTX-MC138, showing safety and disease stabilization in patients with advanced cancer.

Importance Rank:

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.

Cookie settings ACCEPT